bupropion

(redirected from Budeprion XL)
Also found in: Dictionary, Wikipedia.

bupropion

 [bu-pro´pe-on]
a compound structurally similar to amphetamine, used in the form of the hydrochloride salt as an antidepressant and as an aid in smoking cessation to reduce the symptoms of nicotine withdrawal; administered orally.

bupropion

/bu·pro·pi·on/ (bu-pro´pe-on) a monocyclic compound structurally similar to amphetamine, used as the hydrochloride salt as an antidepressant and as an aid in smoking cessation.

bupropion

(byo͞o-prō′pē-ŏn′)
n.
A drug, C13H18ClNO, used in its hydrochloride form for the treatment of depression and as an aid in smoking cessation. It is a weak inhibitor of norepinephrine and dopamine reuptake in the central nervous system.

buPROPion

[boo͡prō′pē·on]
a heterocyclic mood-elevating drug used to treat some types of depression (trademark: Wellbutrin) and also to promote smoking cessation (trademark: Zyban).

bupropion

Zyban® Psychiatry An antidepressant Side effects Dry mouth, insomnia Contraindications Seizures, bulimia

bupropion

A drug used in the treatment of tobacco, drug and alcohol dependency. Bupropion reacts adversely with a wide range of other drugs and may induce seizures in sensitive persons. When used, a strict regime is necessary. A brand name is Zyban.

Bupropion

An antidepressant medication given to smokers for nicotine withdrawal symptoms. It is sold under the trade name Zyban.

bupropion (byōō´prō´pēon),

n brand names: Wellbutrin, Zyban;
drug class: antidepressant;
action: weak uptake inhibitor of dopamine, serotonin, norepinephrine; mechanism unknown;
uses: treatment of depression and anxiety disorders; tobacco cessation.
References in periodicals archive ?
According to the December 2, 2009 article, the proposed study will enroll 138 patients who complained after switching from Wellbutrin XL([R]) 300 mg to Budeprion XL.
A statement in the article attributed to Teva's head of regulatory affairs suggests that the study will rely on blood-level data to verify bioequivalence of Wellbutrin XL([R]) and Budeprion XL.
Budeprion XL is already deemed to be bioequivalent to Wellbutrin XL([R]) by the FDA as defined by existing standard FDA criteria.
However, based on available information, an independent expert retained by Biovail to consider the matter noted, "Even if Wellbutrin XL([R]) and Budeprion XL were found (again) to be bioequivalent according to FDA bioequivalence criteria, the failure to find systematic differences in AUC and Cmax in the study does not exclude the possibility of other between-product differences affecting clinical response.
Biovail believes the size of the proposed Teva study, while much larger than needed for bioequivalence testing, is likely too small to demonstrate that Wellbutrin XL([R])300 mg and Budeprion XL have similar safety, tolerability, and/or efficacy profiles.